Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers.

Aronchik I, Appleton BA, Basham SE, Crawford K, Del Rosario M, Doyle LV, Estacio WF, Lan J, Lindvall MK, Luu CA, Ornelas E, Venetsanakos E, Shafer CM, Jefferson AB.

Mol Cancer Res. 2014 May;12(5):803-12. doi: 10.1158/1541-7786.MCR-13-0595. Epub 2014 Feb 19.

2.

Random peptide bacteriophage display as a probe for urokinase receptor ligands.

Fong S, Doyle MV, Goodson RJ, Drummond RJ, Stratton JR, McGuire L, Doyle LV, Chapman HA, Rosenberg S.

Biol Chem. 2002 Jan;383(1):149-58.

PMID:
11928809
3.

Semirational design of a potent, artificial agonist of fibroblast growth factor receptors.

Ballinger MD, Shyamala V, Forrest LD, Deuter-Reinhard M, Doyle LV, Wang JX, Panganiban-Lustan L, Stratton JR, Apell G, Winter JA, Doyle MV, Rosenberg S, Kavanaugh WM.

Nat Biotechnol. 1999 Dec;17(12):1199-204.

PMID:
10585718
4.

Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth.

Tressler RJ, Pitot PA, Stratton JR, Forrest LD, Zhuo S, Drummond RJ, Fong S, Doyle MV, Doyle LV, Min HY, Rosenberg S.

APMIS. 1999 Jan;107(1):168-73.

PMID:
10190294
5.

Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.

Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S.

Cancer Res. 1996 May 15;56(10):2428-33.

8.
11.
13.

Immunoregulatory T lymphocytes in man. Soluble antigen-specific suppressor-inducer T lymphocytes are derived from the CD4+CD45R-p80+ subpopulation.

Damle NK, Childs AL, Doyle LV.

J Immunol. 1987 Sep 1;139(5):1501-8. Erratum in: J Immunol 1987 Dec 1;139(11):3911.

PMID:
2887618
14.
15.

Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines.

Creasey AA, Doyle LV, Reynolds MT, Jung T, Lin LS, Vitt CR.

Cancer Res. 1987 Jan 1;47(1):145-9.

16.

Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.

Damle NK, Doyle LV, Bradley EC.

J Immunol. 1986 Nov 1;137(9):2814-22.

PMID:
2944965

Supplemental Content

Loading ...
Support Center